SK
Therapeutic Areas
Celloram Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CLM-022 | Not Specified (Oncology/Immune/Metabolic Focus) | Preclinical |
| Sopprimerex | Not Specified (Oncology/Immune/Metabolic Focus) | Preclinical |
| NOVS-100 | Not Specified (Oncology/Immune/Metabolic Focus) | Preclinical |
| Protexi | Not Specified (Oncology/Immune/Metabolic Focus) | Preclinical |
Leadership Team at Celloram
TP
Tej Pareek, PhD, MBA, MPH
President, CEO, Board Director
JL
John Letterio, M.D.
Co-founder and Board Director
SL
Seunghwan Lim, PhD
VP and Director Scientific Operations, Cell Therapy Program
LL
Liraz Levi, PhD
VP and Director Scientific Operations, Small Molecule Program
S(
Sarah (Saerom) Kim
Business Development Advisor